



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 4, 2024

Sujal Patel  
Chief Executive Officer  
Nautilus Biotechnology, Inc.  
2701 Eastlake Avenue East  
Seattle, Washington 98102

**Re: Nautilus Biotechnology, Inc.**  
**Registration Statement on Form S-3**  
**Filed February 28, 2024**  
**File No. 333-277437**

Dear Sujal Patel:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Ansart at 202-551-4511 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Industrial Applications and  
Services

cc: Zachary Myers